PRELIMINARY ANALYSIS OF THE DIAGNOSTIC VALUE AND MECHANISM OF ACTION OF TGFΒI AND S100A4 IN HEPATOCELLULAR CARCINOMA
Abstract
Background: To analyze the diagnostic value of transforming growth factor-beta-induced protein (TGFβI) and S100 calcium-binding protein A4 (S100A4) on hepatocellular carcinoma (HCC), and to further explored the effects of TGFβI and S100A4 on ferroptosis in HCC cells. Methods: We retrospectively analyzed 76 patients with HCC admitted to our hospital from October 2022 to June 2023, and detected the differences in the expression of TGFβI and S100A4 in cancerous tissues and paracancerous tissues to analyze their diagnostic and prognostic assessment value for HCC. Additionally, the HCC cell line HepG2 was purchased and transfected with TGFβI and S100A4 abnormal expression plasmids to check changes in cell viability, oxidative stress damage, mitochondrial damage, and ferroptosis. Results: TGFβI and S100A4 were upregulated in HCC tissues (P<0.05), and their combined detection exhibited excellent diagnostic effects for HCC. The levels of TGFβI and S100A4 in patients who died prognostically were higher than those in surviving patients (P<0.05). An increase in the levels of TGFβI and S100A4 indicates an elevated risk of prognostic death in patients. In cell experiments, upregulating TGFβI and S100A4 expression activated HepG2 activity, inhibited apoptosis, mitochondrial and oxidative stress damage, and improved cell ferroptosis. Conclusions: TGFβI and S100A4 are elevated in HCC and they have the potential to be clinical diagnostic indicators of HCC.
Copyright (c) 2025 Yufeng Zhang, Liang Zhao, Qinghua Shu, Bowen Sha, Miao Wu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.